Suppr超能文献

在一个具有错义突变 A2201P 的轻度血友病 A 家族中,针对因子 VIII 表位的 HLA-DR 限制性 T 细胞反应。

HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.

机构信息

Puget Sound Blood Center, BRI Rm 3016, 921 Terry Avenue, Seattle, WA 98104, USA.

出版信息

Haemophilia. 2010 May;16(102):44-55. doi: 10.1111/j.1365-2516.2008.01905.x.

Abstract

An HLA-DRA-DRB10101-restricted T-cell epitope in the factor VIII (FVIII) C2 domain occurred in a mild haemophilia A patient with missense substitution FVIII-A2201P. His T cells responded to synthetic peptides FVIII(2186-2205) and FVIII(2194-2213) (J Thromb Haemost 2007; 5: 2399). T cells from family members with genotype FVIII-A2201P were analysed to determine if FVIII-specific T cells occur in individuals with a haemophilic mutation but no clinically significant inhibitor response. Fluorescent MHC class II tetramers corresponding to subjects'HLA-DRB1 types were loaded with 20-mer peptides and utilized to label antigen-specific CD4+ T cells. T-cell responses to peptides spanning the FVIII-C2 sequence were evaluated. T cells recognizing specific peptides were cloned, and antigen specificity was verified by proliferation assays. Plasma and/or purified IgG samples were tested for FVIII inhibitory activity. CD4+ T cells and T-cell clones from two brothers who shared the DRB10101 allele responded to FVIII(2194-2213). A haemophilic cousin's HLA-DRA-DRB11104-restricted response to FVIII(2202-2221) was detected only when CD4+CD25+ cells were depleted. A great uncle and two obligate carriers had no detectable FVIII-C2-specific T cells. Concentrated IgG from the brother without a clinical inhibitor response showed a low-titre FVIII inhibitor. FVIII-specific T cells and inhibitory IgG were found in a previously infused, haemophilic subject who had a sub-clinical FVIII inhibitor. CD4+CD25+ depleted T cells from a non-infused haemophilic cousin recognized an overlapping FVIII epitope, indicating a latent HLA-DRA-DRB11104-restricted T-cell response to FVIII. Specific T-cell responses to FVIII can occur without clinically significant inhibitors.

摘要

一个位于因子 VIII(FVIII)C2 结构域的 HLA-DRA-DRB10101 限制性 T 细胞表位出现在一位存在错义替换 FVIII-A2201P 的轻度血友病 A 患者中。他的 T 细胞对合成肽 FVIII(2186-2205) 和 FVIII(2194-2213)有反应(J Thromb Haemost 2007; 5: 2399)。分析了具有 FVIII-A2201P 基因型的家族成员的 T 细胞,以确定是否在存在血友病突变但无临床显著抑制剂反应的个体中存在 FVIII 特异性 T 细胞。与受试者 HLA-DRB1 类型相对应的荧光 MHC Ⅱ四聚体加载了 20 个氨基酸肽,并用于标记抗原特异性 CD4+T 细胞。评估了跨越 FVIII-C2 序列的肽的 T 细胞反应。克隆识别特定肽的 T 细胞,并通过增殖测定验证抗原特异性。测试血浆和/或纯化 IgG 样本的 FVIII 抑制活性。两位共享 DRB10101 等位基因的兄弟的 CD4+T 细胞和 T 细胞克隆对 FVIII(2194-2213)有反应。仅当耗尽 CD4+CD25+细胞时,血友病表亲的 HLA-DRA-DRB11104 限制性对 FVIII(2202-2221)的反应才被检测到。一位没有临床抑制剂反应的叔祖父和两位强制携带者没有检测到 FVIII-C2 特异性 T 细胞。来自无临床抑制剂反应的兄弟的浓缩 IgG 显示出低滴度的 FVIII 抑制剂。在先前输注的、有亚临床 FVIII 抑制剂的血友病患者中发现了 FVIII 特异性 T 细胞和抑制性 IgG。非输注的血友病表亲的耗尽 CD4+CD25+T 细胞识别重叠的 FVIII 表位,表明存在潜在的 HLA-DRA-DRB11104 限制性对 FVIII 的 T 细胞反应。对 FVIII 的特异性 T 细胞反应可能在无临床显著抑制剂的情况下发生。

相似文献

引用本文的文献

6
Specificity of the T Cell Response to Protein Biopharmaceuticals.蛋白类生物制药的 T 细胞反应的特异性。
Front Immunol. 2020 Jul 22;11:1550. doi: 10.3389/fimmu.2020.01550. eCollection 2020.
7
Hemophilia management: Huge impact of a tiny difference.血友病管理:微小差异产生巨大影响。
Res Pract Thromb Haemost. 2020 Feb 28;4(3):377-385. doi: 10.1002/rth2.12314. eCollection 2020 Mar.
10
Tolerating Factor VIII: Recent Progress.耐受因子 VIII:最新进展。
Front Immunol. 2020 Jan 10;10:2991. doi: 10.3389/fimmu.2019.02991. eCollection 2019.

本文引用的文献

7
Genetic risk factors for inhibitors to factors VIII and IX.凝血因子VIII和IX抑制物的遗传风险因素。
Haemophilia. 2006 Dec;12 Suppl 6:15-22. doi: 10.1111/j.1365-2516.2006.01361.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验